Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for OrthoPediatrics's Debt-to-EBITDA or its related term are showing as below:
FRA:2X7'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -21.93 Med: -4.29 Max: -0.05
Current: -21.93
During the past 12 years, the highest Debt-to-EBITDA Ratio of OrthoPediatrics was -0.05. The lowest was -21.93. And the median was -4.29.
FRA:2X7's Debt-to-EBITDA is ranked worse than 100% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs FRA:2X7: -21.93
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
OrthoPediatrics Debt-to-EBITDA Related Terms
OrthoPediatrics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for OrthoPediatrics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2X7 vs NPCE, VREX, OFIX: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, OrthoPediatrics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrthoPediatrics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrthoPediatrics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OrthoPediatrics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
OrthoPediatrics (FRA:2X7) has a Debt-to-EBITDA of 19.08 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OrthoPediatrics. According to the industry distribution chart, OrthoPediatrics ranks #999999 out of 471 companies in the Medical Devices & Instruments industry.
Is OrthoPediatrics' Debt-to-EBITDA too high?
OrthoPediatrics' current Debt-to-EBITDA is 19.08. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. OrthoPediatrics' value of 19.08 is 1063.4% above this industry median. Based on the distribution chart, OrthoPediatrics ranks #999999 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OrthoPediatrics has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does OrthoPediatrics' Debt-to-EBITDA compare to NPCE and VREX?
According to the Medical Devices & Instruments industry distribution chart, OrthoPediatrics ranks #999999 out of 471 companies for Debt-to-EBITDA. This places OrthoPediatrics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. OrthoPediatrics' value of 19.08 is 1063.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrthoPediatrics's current Debt-to-EBITDA of 19.08 is 1063.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OrthoPediatrics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrthoPediatrics's current Debt-to-EBITDA is 19.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrthoPediatrics stock overvalued right now?
OrthoPediatrics (FRA:2X7) has a current Debt-to-EBITDA of 19.08. The stock's GF Value™ is €24.72, compared to a current price of €18.80 — trading 23.9% below its estimated fair value. The current Debt-to-EBITDA is 19.08 and 1063.4% above the Medical Devices & Instruments industry median of 1.64. OrthoPediatrics' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For OrthoPediatrics (FRA:2X7), the current Debt-to-EBITDA is 19.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrthoPediatrics (FRA:2X7) Overvalued in 2026?
Based on GuruFocus' analysis, OrthoPediatrics stock appears to be undervalued.
The current stock price of €18.80 is trading 23.9% below its estimated GF Value™ of €24.72.
Key valuation signals for FRA:2X7:
Debt-to-EBITDA: 19.08
GF Value™: €24.72 vs. price of €18.80 (23.9% below fair value)
Industry Position: 1063.4% above the Medical Devices & Instruments median (#999999 of 471)
No single metric tells the full story. See the FRA:2X7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
84GF Score
Get the complete analysis for FRA:2X7
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2X7 has been successfully added to your 
